Novartis obtained portfolio-level options for exclusive rights to Hybrozyme-enabled SC formulations, with economics up to ...
Marco Anelli, MD | Authors | Pharmaceutical Technology serves as the connection to bio manufacturing and development, featuring regulatory updates and expert industry news.
David S. Thompson, CSAP, is Chief Alliance Officer at Eli Lilly and Company.
The FDA approves zilganersen, the first disease-modifying Alexander disease therapy, offering rare disease developers a trial ...
Novartis's up-to-$3.2 billion licensing deal for Alteogen's ALT-B4 hyaluronidase enzyme is the fourth subcutaneous-conversion ...
Extending CAR T beyond cancer alters risk–benefit calculus, because chronic autoimmune populations have alternative therapies ...
On August 31, 2026, Eli Lilly announced it has entered a definitive agreement to acquire Merida Biosciences, a biotechnology ...
Continuous direct compression can provide a simplified alternative pathway for selected spray-dried dispersion formulations ...
The FDA cleared four notable therapies within the same week in late August, spanning infectious disease, cardiometabolic care ...
Tara Dougal, event director for pharma at Informa Markets and head of CPHI Milan, previews the 2026 show in an interview with ...
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor. PhD, AbbVie, and Swita Singh, PhD, Bristol ...
FDA approves Rasonque (daraxonrasib), the first broad RAS-targeted therapy for metastatic pancreatic cancer, validating RAS ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results